Cuyue Tang1, Thomayant Prueksaritanont. 1. Department of Drug metabolism and Pharmacokinetics, WP75A-203, Merck Research Laboratories, West Point, Pennsylvania, 19486, USA. cuyue_tang@merck.com
Abstract
PURPOSE: To systemically investigate, for a therapeutic protein with a circulating soluble target, how the interplay of target dynamics and drug pharmacokinetics defines the 'total' and 'free' drug and target temporal profiles. METHOD: By extending the established rapid-binding target-mediated drug disposition (TMDD) pharmacokinetic model to circulating soluble targets, the temporal profiles of 'total' and 'free' drug and target were simulated with varying binding affinity (K(D)), target baseline (R(ss)), target turnover, and drug dose level. Two sets of published experimental data were compared with the simulated results. RESULTS: Binding to a circulating soluble target could lead to a divergence of the 'free' drug from the 'total' drug. Simulations show this divergent magnitude determined by K(D) and R(ss), with the temporal profile being defined by target turnover and drug dose level. As divergence proceeds, starting at the distribution phase, 'free' drug would decline faster but eventually parallel 'total' drug at the terminal phase, giving rise to a steeper distribution phase and comparable terminal half-life, relative to the 'total' form. The model also allows for estimation of the dynamic change of 'total' and 'free' target in response to the treatment of a therapeutic protein drug, facilitating dose level and regimen design to achieve desired 'free' target suppression. Model predictions compared favorably with two sets of published experimental data. CONCLUSIONS: Theoretical analyses identified key variables governing the different temporal profiles of 'total' and 'free' drug and target. The rapid-binding TMDD model reasonably captured the features of the interplay of drug pharmacokinetics and target dynamics for two reported cases.
PURPOSE: To systemically investigate, for a therapeutic protein with a circulating soluble target, how the interplay of target dynamics and drug pharmacokinetics defines the 'total' and 'free' drug and target temporal profiles. METHOD: By extending the established rapid-binding target-mediated drug disposition (TMDD) pharmacokinetic model to circulating soluble targets, the temporal profiles of 'total' and 'free' drug and target were simulated with varying binding affinity (K(D)), target baseline (R(ss)), target turnover, and drug dose level. Two sets of published experimental data were compared with the simulated results. RESULTS: Binding to a circulating soluble target could lead to a divergence of the 'free' drug from the 'total' drug. Simulations show this divergent magnitude determined by K(D) and R(ss), with the temporal profile being defined by target turnover and drug dose level. As divergence proceeds, starting at the distribution phase, 'free' drug would decline faster but eventually parallel 'total' drug at the terminal phase, giving rise to a steeper distribution phase and comparable terminal half-life, relative to the 'total' form. The model also allows for estimation of the dynamic change of 'total' and 'free' target in response to the treatment of a therapeutic protein drug, facilitating dose level and regimen design to achieve desired 'free' target suppression. Model predictions compared favorably with two sets of published experimental data. CONCLUSIONS: Theoretical analyses identified key variables governing the different temporal profiles of 'total' and 'free' drug and target. The rapid-binding TMDD model reasonably captured the features of the interplay of drug pharmacokinetics and target dynamics for two reported cases.
Authors: Alicia M Segrave; Donald E Mager; Susan A Charman; Glenn A Edwards; Christopher J H Porter Journal: J Pharmacol Exp Ther Date: 2004-02-10 Impact factor: 4.030
Authors: Karunya K Kandimalla; Geoffry L Curran; Silvina S Holasek; Emily J Gilles; Thomas M Wengenack; Joseph F Poduslo Journal: J Pharmacol Exp Ther Date: 2005-03-02 Impact factor: 4.030
Authors: John S Rudge; Jocelyn Holash; Donna Hylton; Michelle Russell; Shelly Jiang; Raymond Leidich; Nicholas Papadopoulos; Erica A Pyles; Al Torri; Stanley J Wiegand; Gavin Thurston; Neil Stahl; George D Yancopoulos Journal: Proc Natl Acad Sci U S A Date: 2007-11-13 Impact factor: 11.205
Authors: Hans-Peter Gerber; Xiumin Wu; Lanlan Yu; Christian Wiesmann; Xiao Huan Liang; Chingwei V Lee; Germaine Fuh; Christine Olsson; Lisa Damico; David Xie; Y Gloria Meng; Johnny Gutierrez; Racquel Corpuz; Bing Li; Linda Hall; Linda Rangell; Ron Ferrando; Henry Lowman; Franklin Peale; Napoleone Ferrara Journal: Proc Natl Acad Sci U S A Date: 2007-02-20 Impact factor: 11.205
Authors: Mitchell C Brenner; Wojciech Krzyzanski; James Z Chou; Pierre E Signore; Cyra K Fung; David Guzman; Dongxia Li; Weihua Zhang; David R Olsen; Viet-Tam L Nguyen; Carolyn W Koo; Mark D Sternlicht; Kenneth E Lipson Journal: Pharm Res Date: 2016-04-08 Impact factor: 4.200
Authors: J Almquist; M Penney; S Pehrsson; A-S Sandinge; A Janefeldt; S Maqbool; S Madalli; J Goodman; S Nylander; P Gennemark Journal: CPT Pharmacometrics Syst Pharmacol Date: 2016-06-16